Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q3 2016
|
TNXP |
|
Phase 3 Results |
Neurology |
Special Protocol Assessment |
|
05/11/2016
|
AAAP |
|
Phase 3 Results |
Oncology |
Orphan Drug, Priority Review |
|
11/30/2016
|
LXRX |
|
510K Submission |
Oncology |
Orphan Drug, Priority Review |
|
H2 2016
|
OXGN |
|
Phase 2 Results |
Oncology |
Orphan Drug |
|
04/15/2016
|
CHMA |
|
PDUFA |
Endocrine |
Orphan Drug |
|
Q1 2017
|
CAPR |
|
Phase 1/2 Results |
Other |
Orphan Drug |
|
05/09/2016
|
SPPI |
|
PDUFA |
Oncology |
Orphan Drug |
|
H2 2016
|
ARRY |
|
Phase 3 Results |
Oncology |
Orphan Drug |
|
H2 2016
|
RDHL |
|
Phase 3 Results |
Other |
Orphan Drug |
|
Q4 2016
|
KPTI |
|
Phase 2/3 Results |
Oncology |
Orphan Drug |
|